AEVI 002

Drug Profile

AEVI 002

Alternative Names: Anti-CD258 monoclonal antibody; Anti-LIGHT monoclonal antibody; MDGN-002; SAR 252067

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
  • Developer Aevi Genomic Medicine; Kyowa Hakko Kirin; Sanofi; The Childrens Hospital of Philadelphia
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • Discontinued Ulcerative colitis

Most Recent Events

  • 14 Jul 2017 Phase-I clinical trials in Crohn's disease (In adults, Treatment-experienced) in USA (SC) (NCT03169894)
  • 02 Jun 2017 Aevi Genomic Medicine plans a phase I trial for Crohn's Disease in USA (SC) (NCT03169894)
  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top